[1]
Tollin M, Bergsson G, Kai-Larsen Y, Lengqvist J, Sjövall J, Griffiths W, Skúladóttir GV, Haraldsson A, Jörnvall H, Gudmundsson GH, Agerberth B. Vernix caseosa as a multi-component defence system based on polypeptides, lipids and their interactions. Cellular and molecular life sciences : CMLS. 2005 Oct:62(19-20):2390-9
[PubMed PMID: 16179970]
Level 3 (low-level) evidence
[2]
SHULAK B. THE ANTIBACTERIAL ACTION OF VERNIX CASEOSA. Harper Hospital bulletin. 1963 Jul-Aug:21():111-7
[PubMed PMID: 14042885]
Level 3 (low-level) evidence
[3]
SPRUNT K, REDMAN WM. VERNIX CASEOSA AND BACTERIA. American journal of diseases of children (1960). 1964 Feb:107():125-30
[PubMed PMID: 14091817]
Level 3 (low-level) evidence
[4]
Visscher MO, Narendran V, Pickens WL, LaRuffa AA, Meinzen-Derr J, Allen K, Hoath SB. Vernix caseosa in neonatal adaptation. Journal of perinatology : official journal of the California Perinatal Association. 2005 Jul:25(7):440-6
[PubMed PMID: 15830002]
Level 3 (low-level) evidence
[5]
Hoeger PH, Schreiner V, Klaassen IA, Enzmann CC, Friedrichs K, Bleck O. Epidermal barrier lipids in human vernix caseosa: corresponding ceramide pattern in vernix and fetal skin. The British journal of dermatology. 2002 Feb:146(2):194-201
[PubMed PMID: 11903227]
Level 3 (low-level) evidence
[6]
Pickens WL, Warner RR, Boissy YL, Boissy RE, Hoath SB. Characterization of vernix caseosa: water content, morphology, and elemental analysis. The Journal of investigative dermatology. 2000 Nov:115(5):875-81
[PubMed PMID: 11069626]
Level 3 (low-level) evidence
[7]
Rissmann R, Groenink HW, Weerheim AM, Hoath SB, Ponec M, Bouwstra JA. New insights into ultrastructure, lipid composition and organization of vernix caseosa. The Journal of investigative dermatology. 2006 Aug:126(8):1823-33
[PubMed PMID: 16628195]
Level 3 (low-level) evidence
[8]
Checa A, Holm T, Sjödin MO, Reinke SN, Alm J, Scheynius A, Wheelock CE. Lipid mediator profile in vernix caseosa reflects skin barrier development. Scientific reports. 2015 Nov 2:5():15740. doi: 10.1038/srep15740. Epub 2015 Nov 2
[PubMed PMID: 26521946]
Level 3 (low-level) evidence
[9]
Míková R, Vrkoslav V, Hanus R, Háková E, Hábová Z, Doležal A, Plavka R, Coufal P, Cvačka J. Newborn boys and girls differ in the lipid composition of vernix caseosa. PloS one. 2014:9(6):e99173. doi: 10.1371/journal.pone.0099173. Epub 2014 Jun 9
[PubMed PMID: 24911066]
Level 3 (low-level) evidence
[10]
Tollin M, Jägerbrink T, Haraldsson A, Agerberth B, Jörnvall H. Proteome analysis of vernix caseosa. Pediatric research. 2006 Oct:60(4):430-4
[PubMed PMID: 16940245]
Level 3 (low-level) evidence
[11]
Liu S, Zhang H, Duan E. Epidermal development in mammals: key regulators, signals from beneath, and stem cells. International journal of molecular sciences. 2013 May 24:14(6):10869-95. doi: 10.3390/ijms140610869. Epub 2013 May 24
[PubMed PMID: 23708093]
[13]
Hu MS, Borrelli MR, Hong WX, Malhotra S, Cheung ATM, Ransom RC, Rennert RC, Morrison SD, Lorenz HP, Longaker MT. Embryonic skin development and repair. Organogenesis. 2018 Jan 2:14(1):46-63. doi: 10.1080/15476278.2017.1421882. Epub 2018 Feb 15
[PubMed PMID: 29420124]
[14]
Buchman AL. Glutamine: is it a conditionally required nutrient for the human gastrointestinal system? Journal of the American College of Nutrition. 1996 Jun:15(3):199-205
[PubMed PMID: 8935435]
[15]
Hoath SB, Pickens WL, Visscher MO. The biology of vernix caseosa. International journal of cosmetic science. 2006 Oct:28(5):319-33. doi: 10.1111/j.1467-2494.2006.00338.x. Epub
[PubMed PMID: 18489296]
Level 3 (low-level) evidence
[16]
Hoeger PH, Enzmann CC. Skin physiology of the neonate and young infant: a prospective study of functional skin parameters during early infancy. Pediatric dermatology. 2002 May-Jun:19(3):256-62
[PubMed PMID: 12047648]
[17]
Nishijima K, Yoneda M, Hirai T, Takakuwa K, Enomoto T. Biology of the vernix caseosa: A review. The journal of obstetrics and gynaecology research. 2019 Nov:45(11):2145-2149. doi: 10.1111/jog.14103. Epub 2019 Sep 10
[PubMed PMID: 31507021]
Level 3 (low-level) evidence
[18]
SAUNDERS C. The vernix caseosa and subnormal temperature in premature infants. The Journal of obstetrics and gynaecology of the British Empire. 1948 Aug:55(4):442-4
[PubMed PMID: 18878967]
Level 3 (low-level) evidence
[19]
Akinbi HT, Narendran V, Pass AK, Markart P, Hoath SB. Host defense proteins in vernix caseosa and amniotic fluid. American journal of obstetrics and gynecology. 2004 Dec:191(6):2090-6
[PubMed PMID: 15592296]
Level 3 (low-level) evidence
[20]
Bergsson G, Arnfinnsson J, Steingrímsson O, Thormar H. Killing of Gram-positive cocci by fatty acids and monoglycerides. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. 2001 Oct:109(10):670-8
[PubMed PMID: 11890570]
[21]
Visscher M, Narendran V. The Ontogeny of Skin. Advances in wound care. 2014 Apr 1:3(4):291-303
[PubMed PMID: 24761361]
Level 3 (low-level) evidence
[23]
Roos TC, Geuer S, Roos S, Brost H. Recent advances in treatment strategies for atopic dermatitis. Drugs. 2004:64(23):2639-66
[PubMed PMID: 15537368]
Level 3 (low-level) evidence
[24]
Larson AA, Dinulos JG. Cutaneous bacterial infections in the newborn. Current opinion in pediatrics. 2005 Aug:17(4):481-5
[PubMed PMID: 16012260]
Level 3 (low-level) evidence
[25]
Haubrich KA. Role of Vernix caseosa in the neonate: potential application in the adult population. AACN clinical issues. 2003 Nov:14(4):457-64
[PubMed PMID: 14595204]
Level 3 (low-level) evidence
[26]
Visscher MO, Barai N, LaRuffa AA, Pickens WL, Narendran V, Hoath SB. Epidermal barrier treatments based on vernix caseosa. Skin pharmacology and physiology. 2011:24(6):322-9. doi: 10.1159/000328744. Epub 2011 Aug 4
[PubMed PMID: 21822033]
Level 3 (low-level) evidence
[27]
Moore C, Dempsey D, Deitermann D, Lewis D, Leikin J. Fetal cocaine exposure: analysis of vernix caseosa. Journal of analytical toxicology. 1996 Oct:20(6):509-11
[PubMed PMID: 8889690]
Level 3 (low-level) evidence
[28]
Gray T, Huestis M. Bioanalytical procedures for monitoring in utero drug exposure. Analytical and bioanalytical chemistry. 2007 Aug:388(7):1455-65
[PubMed PMID: 17370066]
[29]
Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics. 2008 Oct:122(4):812-24. doi: 10.1542/peds.2007-2232. Epub
[PubMed PMID: 18829806]
[30]
McKenna SP, Doward LC. Quality of life of children with atopic dermatitis and their families. Current opinion in allergy and clinical immunology. 2008 Jun:8(3):228-31. doi: 10.1097/ACI.0b013e3282ffd6cc. Epub
[PubMed PMID: 18560297]
Level 2 (mid-level) evidence
[31]
Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march. The Journal of allergy and clinical immunology. 2016 Aug:138(2):350-358.e1. doi: 10.1016/j.jaci.2016.06.002. Epub 2016 Jun 22
[PubMed PMID: 27497277]
[32]
Visscher MO, Adam R, Brink S, Odio M. Newborn infant skin: physiology, development, and care. Clinics in dermatology. 2015 May-Jun:33(3):271-80. doi: 10.1016/j.clindermatol.2014.12.003. Epub 2014 Dec 8
[PubMed PMID: 25889127]
[33]
Holm T, Rutishauser D, Kai-Larsen Y, Lyutvinskiy Y, Stenius F, Zubarev RA, Agerberth B, Alm J, Scheynius A. Protein biomarkers in vernix with potential to predict the development of atopic eczema in early childhood. Allergy. 2014 Jan:69(1):104-12. doi: 10.1111/all.12308. Epub 2013 Nov 11
[PubMed PMID: 24205894]
[34]
Csete K, Beer Z, Varga T. Prenatal and newborn paternity testing with DNA analysis. Forensic science international. 2005 Jan 17:147 Suppl():S57-60
[PubMed PMID: 15694732]
[35]
Stuart OA, Morris AR, Baber RJ. Vernix caseosa peritonitis - no longer rare or innocent: a case series. Journal of medical case reports. 2009 Feb 10:3():60. doi: 10.1186/1752-1947-3-60. Epub 2009 Feb 10
[PubMed PMID: 19208257]
Level 2 (mid-level) evidence
[36]
Val-Bernal JF, Mayorga M, García-Arranz P, Salcedo W, León A, Fernández FA. Vernix caseosa peritonitis: report of two cases. Turk patoloji dergisi. 2015:31(1):51-5
[PubMed PMID: 25110245]
Level 3 (low-level) evidence
[37]
Sadath SA, Abo Diba FI, Nayak S, Shamali IA, Diejomaoh MF. Vernix caseosa peritonitis after vaginal delivery. Clinical medicine insights. Case reports. 2013:6():147-52. doi: 10.4137/CCRep.S12771. Epub 2013 Oct 10
[PubMed PMID: 24151427]
Level 3 (low-level) evidence
[38]
Chambers AC,Patil AV,Alves R,Hopkins JC,Armstrong J,Lawrence RN, Delayed presentation of vernix caseosa peritonitis. Annals of the Royal College of Surgeons of England. 2012 Nov
[PubMed PMID: 23131223]
Level 3 (low-level) evidence
[39]
O'Grady JP, Prefontaine M, Hoffman DE. Vernixuria: another sign of uterine rupture. Journal of perinatology : official journal of the California Perinatal Association. 2003 Jun:23(4):351-2
[PubMed PMID: 12774148]
[40]
Nishijima K, Shukunami K, Inoue S, Kotsuji F. Management for neonatal aspiration syndrome caused by vernix caseosa. Fetal diagnosis and therapy. 2005 May-Jun:20(3):194-6
[PubMed PMID: 15824497]
Level 3 (low-level) evidence
[41]
Ohlsson A, Cumming WA, Najjar H. Neonatal aspiration syndrome due to vernix caseosa. Pediatric radiology. 1985:15(3):193-5
[PubMed PMID: 3991261]
Level 3 (low-level) evidence
[42]
Nakwan N,Kamolvisit W,Napapongsuriya C,Chaiwiriyawong P,Charoenlap C, Fatal Vernix Caseosa Aspiration Associated With Persistent Pulmonary Hypertension of the Newborn. Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society. 2017 Mar-Apr;
[PubMed PMID: 28326961]
Level 3 (low-level) evidence
[43]
Rissmann R, Oudshoorn MH, Zwier R, Ponec M, Bouwstra JA, Hennink WE. Mimicking vernix caseosa--preparation and characterization of synthetic biofilms. International journal of pharmaceutics. 2009 May 8:372(1-2):59-65. doi: 10.1016/j.ijpharm.2009.01.013. Epub 2009 Jan 21
[PubMed PMID: 19429269]
Level 3 (low-level) evidence